Tier 2 — strong

Application of glycine in acute alcohol hallucinosis

Aliyev NA, Aliyev ZN
Human psychopharmacology 2005 20(8):591-594

Bibliography

PubMed
PMID 16247737
DOI
10.1002/hup.735
Funding
Funding was not specified in the indexed abstract; the full funding disclosure has not been verified.
Competing interests
The accessible abstract does not establish the authors' competing interests; absence of a statement is not evidence of no conflicts.

Study snapshot

DesignRandomized controlled human intervention
ModelAdult humans
Sample40 adults with acute alcohol hallucinosis; 20 per group
InterventionSublingual glycine 700 mg/day versus placebo, without other psychotropic medication
Duration7 days
EndpointsSeverity of alcohol hallucinosis

What the study showed, in plain terms

A small study reported reduced hallucinosis severity with sublingual glycine. This historical result is specific to an acute clinical condition and route.

Key findings

  • Symptom severity favored glycine during the seven-day treatment.
  • The study tested sublingual administration, not an ordinary bedtime powder regimen.

What this study can and cannot tell us

Small, brief trial with limited independent replication.

It does not show that glycine treats alcohol withdrawal or reduces alcohol consumption generally.

Related papers in the corpus

Tier 2
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments
Buchanan RW et al. · The American journal of psychiatry · 2007
Tier 2
Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia
Potkin SG et al. · The American journal of psychiatry · 1999
Tier 2
High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia
Heresco-Levy U et al. · Biological psychiatry · 2004
Tier 2
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia
Heresco-Levy U et al. · Archives of general psychiatry · 1999
Tier 2
Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia
Heresco-Levy U et al. · The British journal of psychiatry : the journal of mental science · 1996
Tier 2
Amelioration of negative symptoms in schizophrenia by glycine
Javitt DC et al. · The American journal of psychiatry · 1994

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction